



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO - 1449 FORM

ATTY. DOCKET NO.
11245/46405

SERIAL NO.
10/661,881

APPLICANT
WAKSAL et al.

FILING DATE
September 11, 2003

GROUP
1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCL ASS	FILING DATE
/ALH/	4,863,902	September 5, 1989	Amagase et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/ALH/	EP 332 424	March 25, 1992					

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
/ALH/	Bonner, J.A., et al., "The Interaction of Epidermal Growth Factor and Radiation in Human Head and Neck Squamous Cell Carcinoma Cell Lines With Vastly Different Radiosensitivities", Int. J. Radiation Oncology Biol. Phys., Vol. 29 No. 2, pp.243-247, 1994	
	Huang, S., et al., ABSTRACT in Proceedings of the American Association for Cancer Research Vol. 39, March 1998	
	Huang, SM, et al., "Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck", Cancer Research, Vol. 59, pp. 1935-1940 April 15, 1999	
	Messa, C., et al., "EGF, TGF- α and EGF-R in Human Colorectal Adenocarcinoma", Acta Oncologica, Vol. 37, No. 3, pp. 285-289, 1998	
	Real, F.X., "Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues: Relationship to Cell Lineage and Stage of Differentiation", Cancer Research Vol. 46, pp. 4726-4731, September 1986	
	Masui, H., et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies", Cancer Research Vol. 44, pp. 1002-1007, March 1984	
	Goldstein, N.I., et al., "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model", Clinical Cancer Research, Vol. 1, pp. 1311-1318, November 1995	
	Wells, W., et al., "EGF Receptor and p185 ^{erbB-2} -Specific Single-Chain Antibody Toxins Differ in Their Cell-Killing Activity on Tumor Cells Expressing Both Receptor Proteins" Int. J. Cancer, Vol. 60, pp. 137-144, 1995	
	Moyer, J.D., "Induction of Apoptosis and Cell Cycle Arrest by CP-358, 774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase" Cancer Research Vol. 57, pp. 4838-4848, November 1, 1997	
	Prewett, M., "The biologic Effects of C225, A Chimeric Monoclonal antibody to the EGFR, on Human Prostate Carcinoma", Journal of Immunotherapy, Vol. 19, No. 6, pp. 419-427, 1997	
	Baselga, J., and Mendelsohn, J., "The epidermal growth factor receptor as a target for the therapy in breast carcinoma", Breast Cancer Research and Treatment, Vol. 29, pp. 127-138, 1994	
	Baselga, J., et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal antibodies", Journal of the National Cancer Institute, Vol. 85, No. 16, August 18, 1993	

EXAMINER	/Anne Holleran/ (03/19/2007)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

JUN 26 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 FORM	ATTY. DOCKET NO. 11245/46405	SERIAL NO. 10/661,881
	APPLICANT WAKSAL et al.	
	FILING DATE September 11, 2003	GROUP 1642

U. S. PATENT DOCUMENTS

EXAMINE R INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCL ASS	FILING DATE
/ALH/	6,217,866	April 17, 2001	Schlessinger			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER INITIAL		

EXAMINER /Anne Holleran/ (03/19/2007)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

NY01192044